Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358637 | 0.89 | ATM (0.53) | ATMCTSKCYP3A4TSHRELANE | |
| SCHEMBL4678519 | 0.85 | CTSK (0.53) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL7275098 | 0.83 | CTSK (0.50) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL7275090 | 0.83 | CTSK (0.50) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL7275095 | 0.83 | CTSK (0.50) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL4676446 | 0.81 | CTSK (0.66) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12590838 | 0.79 | ATM (0.56) | ATMCTSKCYP3A4TSHRELANE | |
| SCHEMBL6356795 | 0.79 | CTSK (0.51) | ATMCTSKCTSSCTSLCTSB | |
| SCHEMBL4674918 | 0.79 | CTSK (0.65) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4674921 | 0.79 | CTSK (0.65) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2379513-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ATM 1715/4885CTSK 1908/4885CYP3A4 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.